There is increasing attention about managing the adverse effects of adjuvant therapy
(Chemotherapy and anti-estrogen treatment) for breast cancer survivors (BCSs) …

Genitourinary syndrome of menopause is a common condition that left untreated can
progress and negatively affect quality of life and sexual function. Laser therapy has a …

Objectives: To assess the effect of microablative fractional CO2 laser (MFCO2-Laser)
therapy on the vaginal microenvironment of postmenopausal women. Methods: Three laser …

It is well established that cancer and its treatment, whether by chemotherapy, radiotherapy,
hormone therapy, or surgery, can adversely impact reproductive function in both women and …

Purpose Vulvovaginal atrophy (VVA) is a commonly reported issue among breast cancer
patients, and its aetiology is multifactorial. Treatment is difficult in these women, particularly …

Introduction Genitourinary syndrome of menopause (GSM) is caused by hypo-estrogenism,
resulting in vaginal dryness, pain, dyspareunia, and urinary tract infection. It is more severe …

Objective: Vulvovaginal atrophy (VVA) is a condition frequently observed in menopause. Its
symptoms can significantly affect the quality of life of patients. Since VVA is related to …

There is increasing attention and concern about managing the adverse effects of adjuvant
endocrine therapy for women with early breast cancer as the side effects of therapy …

The composition of vaginal microbiome in menopause and cancer survivor women changes
dramatically leading to genitourinary syndrome of menopause (GSM) in up to 70% of …

Vulvovaginal atrophy (VVA) is a chronic condition resulting from reduced estrogen levels
during menopause. The North American Menopause Society and the International Society …